查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854493

鞘內幫浦市場按幫浦類型、藥物類型、治療領域和最終用戶分類 - 全球預測 2025-2032

Intrathecal Pumps Market by Pump Type, Drug Type, Therapy Area, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鞘內泵市場規模將達到 9.9161 億美元，複合年成長率為 9.06%。

關鍵市場統計數據
基準年2024年 4.9522億美元
預計年份：2025年 5.4067億美元
預測年份 2032 9.9161億美元
複合年成長率 (%) 9.06%

本書權威地介紹了鞘內泵療法的發展歷程、臨床重點、監管預期以及決定其應用的相關人員。

鞘內泵療法已從一種小眾臨床干預手段發展成為全身性治療無效或產生難以接受的副作用時，治療複雜疼痛和痙攣的核心手段。在過去十年間，臨床醫生拓展了適應症範圍並最佳化了患者選擇，而工程師則提高了設備的可靠性、藥物傳輸的精確度和可程式設計。因此，鞘內泵生態系統如今涵蓋了眾多利益相關者，包括植入醫生、設備相關人員、醫院採購團隊、門診中心、支付方以及尋求持久症狀控制並降低全身風險的患者。

先進輸注演算法和整合遠端監測的引入，正將爭論的焦點從是否進行鞘內注射轉移到如何最佳化長期門診治療。同時，監管機構日益關注上市後監測以及人機互動風險，促使製造商加強對臨床證據和生命週期管理的投入。總而言之，這些發展給臨床領導者和商業策略家帶來了挑戰，他們需要在一個更為複雜的環境中應對，在這個環境中，決定產品應用軌蹟的不再僅僅是產品的新穎性，而是安全性、療效、服務和成本效益。

本執行摘要總結了目前影響鞘內幫浦治療的臨床、商業和政策動態。它闡述了影響相關人員決策的轉型框架，重點介紹了關稅主導的供應鏈在2025年之前的影響，並提取了相關人員需要考慮的細分市場、區域和競爭考察。其目標是為高階主管和臨床領導者提供一個連貫且可操作的基礎，以便將產品開發、市場推廣和業務策略與不斷變化的患者和系統需求相協調。

技術創新在設備工程、遠端監測、臨床實踐和監管預期等方面的融合，正在重塑醫療技術的應用路徑和醫療服務模式。

鞘內幫浦領域正受到技術、臨床實務和醫療服務模式等多面向因素的共同影響而改變。設備層面的創新優先考慮設備的使用壽命和精準度，而電池和導管介面的改進則旨在降低再次手術率並提高患者的便利性。同時，遠端監測和數位遙測技術的整合使得設備相關併發症的早期發現和劑量調整的快速進行成為可能，從而影響後續的治療流程和臨床資源的分配。

臨床實踐正從獨立的門診計畫轉向混合監測模式，該模式結合了定期面對面評估和數據驅動的遠端調整。這種轉變正在改變傳統的以醫院為中心的轉診模式，並支持門診手術中心在移植和追蹤方面的廣泛應用。同時，對鴉片類藥物管理的日益重視以及鞘內注射Baclofen治療痙攣的證據不斷增加，引發了關於患者選擇標準和長期管理路徑的討論。這種臨床轉變對實證醫學的產生、病人教育和跨學科護理協調提出了新的要求。

監管和報銷環境也在不斷演變。監管機構優先考慮對器械-藥物組合產品進行強力的上市後監測和清晰的標籤標註，要求製造商證明其生命週期安全性。支付者則更密切地關注長期價值提案，不僅關注急性手術成本，還關注諸如減少全身用藥、住院次數和減輕看護者負擔等結果。因此，商業策略越來越重視真實世界證據的收集、基於價值的合約試點以及與醫療系統的夥伴關係，以展示能夠同時支持臨床結果和經濟目標的整合式醫療路徑。

總而言之，這些變革性轉變不僅重塑了產品藍圖，也重塑了鞘內療法規模化所需的營運和商業架構。能夠有效推動變革的相關人員，應將設備性能與醫療服務創新和循證實踐相結合，從而降低推廣門檻，並確保與醫療服務提供者和支付方建立長期的治療夥伴關係。

重點闡述了2025年關稅調整如何迫使供應鏈、籌資策略和設計快速調整，以保障臨床服務的連續性和利潤率。

2025年的貿易政策變化和關稅調整為鞘內泵供應鏈和籌資策略引入了新的變數。部分醫療設備組件和進口次組件的關稅上調，增加了依賴地理分散生產網路的製造商的投入成本。為因應此變化，各公司加快了供應商多元化策略，重新評估了其採購佈局，並優先與那些在前置作業時間和價格方面提供更高透明度和靈活性的供應商簽訂合約。除了這些供應方面的應對措施外，各公司還進行了營運方面的調整，例如增加關鍵導管和電子組件的庫存緩衝，以及實施更嚴格的零件認證流程。

臨床醫師和醫院採購團隊觀察到，前置作業時間間歇性延長以及緊急病例的優先分配更為頻繁，都對後續流程產生了影響。由於短期供應商難以承受關稅相關的成本壓力，門診手術中心更重視庫存管理。同時，一些製造商實施了有針對性的價格調整和服務合約修訂，以抵消不斷上漲的投入成本，同時保障高風險患者獲得必要的治療方法。

圍繞關稅永久性的政策不確定性促使企業進行了一些策略調整，這些調整可能會持續到2025年以後。製造商加大了近岸外包和本地化力度，以減輕跨境關稅的影響，而製造外包則在低關稅地區擴大了產能。此外，企業越來越關注供應鏈彈性設計，即透過零件的標準化和模組化來減少對單一來源、受關稅影響的零件的依賴。這些調整提高了中期供應的連續性，但也需要資本投資和跨部門協調，從而影響了短期利潤率和產品上市時間表。

對醫療保健產業的領導者而言，2025 年關稅環境帶來的啟示是，供應鏈韌性如今已成為臨床連續性規劃的策略要素。採購團隊和醫療設備申辦方正日益加強在緊急應變計畫方面的合作，包括雙源採購策略和上游供應商風險的可視性。由於關稅波動仍是規劃中需要考慮的因素，那些在其營運模式中融入靈活採購、緩衝策略和積極供應商溝通的機構，將更有利於維持治療藥物的供應並保障患者的診療路徑。

全面的細分洞察揭示了設備類型、藥物選擇、治療適應症和護理環境如何相互作用，從而決定臨床工作流程和商業化策略。

要了解治療效果和商業化路徑，需要深入了解構成鞘內幫浦市場的產品和臨床細分。根據泵的類型，治療方法方案涵蓋了用於短期或住院治療的體外佩戴式輸注系統，以及用於慢性、長期鞘內治療的植入式泵，每種泵在易用性、感染控制和維護方面都有其獨特的考慮。這些設備類別會影響臨床醫師的工作流程，也會影響治療地點。植入式系統通常需要專門的手術環境和長期追蹤基礎設施，而體外設備通常適用於急性期或過渡期治療。

藥物製劑和相容性直接影響臨床方案和標籤。根據藥物類型，鞘內治療包括使用Baclofen（用於標靶控制痙攣）、局部麻醉劑（用於局部鎮痛）以及鴉片類藥物（用於難治性癌症和嚴重慢性疼痛）。每類藥物都有其獨特的耐受性、給藥方式和監測要求，因此臨床醫生需要根據具體情況調整裝置程序和追蹤頻率，以降低導管相關性肉芽腫和全身性副作用等風險。因此，鞘內藥物的選擇與藥理學、裝置選擇和病人諮詢密切相關。

治療應用進一步完善了護理路徑。根據治療領域，鞘內介入治療可應用於疼痛管理和痙攣管理。疼痛管理本身又分為癌症疼痛和慢性非癌症疼痛，不同族群在植入選擇、鴉片類藥物管理實務和安寧療護整合方面有顯著差異。痙攣管理涵蓋腦性麻痹、多發性硬化症和脊髓損傷等疾病，每種疾病都有其獨特的功能目標、多學科照護需求和長期復健意義。針對這些臨床亞人群客製化設備功能和服務模式，可以提高患者的依從性和功能預後。

終端用戶動態同樣會影響部署和服務模式。基於終端使用者的採用途徑包括門診手術中心、醫院和專科診所，它們各自擁有不同的營運能力、報銷環境和人員配備模式。由於效率高且符合病患偏好，門診手術中心越來越傾向於進行擇期植入手術，而醫院通常需要處理病情更為複雜的病例和更高的手術全期風險。提供長期設備程式設計和多學科追蹤的專科診所對於維持治療效果和收集結果數據至關重要。了解這些細分視角之間的交集對於設計符合醫療服務實際情況的市場推廣策略、臨床醫生教育計畫和長期服務方案至關重要。

關鍵區域洞察闡述了美洲、歐洲、中東和非洲以及亞太地區的監管、報銷和基礎設施現狀將如何影響科技的採納和普及策略。

區域動態影響鞘內幫浦的臨床應用、監管環境和供應鏈設計。在美洲，緊密的學術中心和社區醫院網路支援早期應用，並進行了完善的核准後臨床研究。該地區複雜的醫保報銷流程和支付方的監管影響申辦方對證據生成的優先排序，而一體化的醫院系統則支持整合式護理路徑，從而促進長期追蹤和設備維護。因此，製造商通常會根據醫療系統的證據需求和價值驗證試驗來制定打入市場策略。

歐洲、中東和非洲的監管和報銷環境各不相同，這迫使企業採取靈活的打入市場策略。西方國家通常強調療效比較和衛生技術評估框架，鼓勵製造商投資於真實世界結果和成本效益研究。相較之下，中東和非洲部分地區則優先考慮准入和基礎設施建設，這可能為有針對性的能力建設方案和本地夥伴關係創造機會。如果證據和服務支持到位，某些地區的跨境監管協調工作和集中採購機制可以加速技術應用。

亞太地區既有監管體系完善的成熟市場，也有對專業醫療基礎設施快速投資的新興市場。在該地區已開發國家，臨床創新者和私人醫療系統推動了對高效能醫療器材和綜合服務模式的需求。而在新興市場，需求往往受到手術能力投資、疾病負擔變化以及地區報銷政策的影響。尋求區域規模的開發商通常採用混合策略，將成熟市場的直接佈局與新興市場的經銷商夥伴關係及培訓計畫相結合，以確保臨床應用的成功和醫療服務的連續性。

這些因素包括在本地建立實證基礎的必要性、對移植和追蹤臨床團隊進行培訓的重要性，以及供應鏈韌性的價值。根據當地的監管、支付方和基礎設施實際情況調整商業性和臨床策略，可以加快技術推廣應用，同時確保不同醫療保健系統都能獲得治療並發揮其臨床療效。

關鍵的公司層面洞察揭示了現有企業和創新參與企業如何透過臨床證據、服務模式和軟體差異化來競爭。

鞘內幫浦市場的競爭格局反映了現有設備的可靠性與針對特定臨床需求的專業創新者崛起之間的平衡。現有製造商憑藉長期的臨床數據、廣泛的服務網路以及降低植入風險並支持後續護理的全面培訓項目，保持市場優勢。這些優勢增強了機構的信心，並簡化了醫院和專科診所的採購決策，這些機構的臨床團隊需要高可靠性和完善的售後支援。

同時，新參與企業和相關醫療技術公司正透過軟體賦能功能、遠端監控和模組化設計理念來凸顯自身優勢，這些理念強調易於編程和減少維護。這些產品吸引了注重門診病人照護模式的醫療系統和尋求更精細劑量調整能力的專家。設備開發商和製藥公司之間的合作也在不斷增加，尤其是在藥物-器械聯合治療策略方面，共同開發可以簡化標籤和臨床試驗設計。

服務和商業模式正日益成為競爭定位的核心。提供全面臨床醫生培訓、現場技術支援以及透明的保固和更換政策的公司，能夠增強臨床路徑的依賴。此外，投資於結果註冊和真實世界證據舉措的供應商，能夠與支付方和醫療系統建立更強力的價值主張。與醫院、學術中心和復健網路建立策略夥伴關係，透過將設備納入既定的護理路徑，進一步擴大了覆蓋範圍並促進了產品的採用。

對於採購者和醫療系統領導者而言，供應商的選擇不再僅僅取決於設備功能，而是受到更廣泛因素的影響。總醫療成本、服務品質、實證實踐以及在診療路徑重塑方面的合作能力都變得同等重要。因此，能夠整合臨床支援、資訊服務和靈活商業性安排的供應商，更有可能贏得長期夥伴關係，並在複雜的醫療服務系統中推廣鞘內治療。

為醫療器材製造商、臨床醫生和支付方提供切實可行的建議，以協調實證醫學、數位化能力、供應鏈韌性和商業模式，以實現永續成長。

產業領導者必須採取果斷行動，使產品藍圖、臨床證據產生和供應鏈韌性與不斷發展的醫療服務模式保持一致。首先，應優先考慮將設備性能與具有臨床意義的結果聯繫起來的綜合價值證明，例如減少全身用藥、降低住院率以及改善痙攣患者的功能狀態。儘早與支付方和大型醫療系統合作，制定切實可行的證據收集舉措，將有助於縮短報銷核准流程，並支持基於價值的合約試點項目。

其次，投資遠端監測和遠端檢測技術，以實現混合追蹤模式，並在不影響安全性的前提下減少門診就診次數。遠端資料流不僅提升了患者的便利性，還能提供實際應用的終點指標，進而增強經濟效益。此外，配合臨床醫生培訓項目，使更廣泛的外科和專科診所網路能夠採用植入和編程通訊協定，可以將適用的醫療服務擴展到三級醫療中心以外的場所。

第三，制定供應鏈策略，強調雙重採購、盡可能實現在地化生產，並採用以供應為導向的設計方法，減少對受關稅影響零件的依賴。策略性庫存管理和供應商夥伴關係可以保障淨利率，同時因應短期供應中斷。此外，還應與復健和安寧療護機構建立夥伴關係，將鞘內治療納入多學科診療路徑，以提高患者識別率和治療連續性。

最後，要圍繞服務和結果而非硬體銷售來建立商業模式。盡可能提供靈活的合約、保固方案和基於結果的附加條款，以使獎勵與購買者保持一致。透過將實證實踐、數位化能力和穩健營運整合到一套連貫的打入市場策略中，行業領導者將能夠更好地擴大治療方法規模，同時應對支付方的監管和臨床醫生的期望。

我們採用透明嚴謹的調查方法，結合臨床醫生訪談、法規和文獻審查、供應鏈分析以及同行評審檢驗，以確保獲得可操作的洞見。

本調查方法採用多種方法，確保研究結果的嚴謹性和可重複性。主要研究包括對移植醫生、採購負責人和臨床專案經理進行結構化訪談，以了解操作流程、病患選擇標準和後續工作流程。這些第一手觀點，以及由臨床醫生組成的顧問專題研討會的意見，檢驗了臨床假設，並突顯了在不同醫療機構推廣鞘內治療所面臨的實際障礙。

二次研究涵蓋了監管文件、同行評審的臨床文獻和操作最佳實踐指南，以收集安全訊號和設備性能主題。分析了產品技術規格和服務模式描述，以發現新興的設計趨勢和供應商能力。此外，還分析了臨床註冊摘要和已發表的結果研究，以綜合分析與Baclofen治療、局部麻醉劑使用和鴉片類藥物輔助鞘內注射相關的治療和安全性敘述。

我們的供應鏈和政策分析利用關稅和貿易出版物、公開的關稅表以及採購案例研究，評估了2025年關稅變化對營運的影響。我們運用情境分析技術評估了可能的供應方應對措施，包括近岸外包、雙重採購和庫存策略，以了解其對製造商和醫療保健提供者的影響。研究結果透過跨部門同行評審檢驗，以確保其具有實際意義和事實準確性。

此研究方法優先考慮透明度和可重複性。資料缺口均已記錄，並透過後續訪談和保守的解讀予以彌補。這種嚴謹的調查方法確保了結論基於當前的臨床實踐、監管現實以及鞘內泵生態系統中相關人員面臨的營運限制。

簡潔的結論強調了在獲取臨床價值、確保供應彈性以及使證據與支付方和提供者的需求保持一致方面的關鍵策略要務。

鞘內幫浦治療正處於曲折點，臨床前景、技術能力和政策動態在此交匯，為相關人員創造了新的機會和責任。設備設計和遙測技術的進步正在推動更安全、以患者為中心的護理模式的發展，而不斷變化的支付方期望和監管重點則要求提供更有力的證據和更完善的生命週期管理。 2025年關稅上調的經驗凸顯了分散式供應鏈的脆弱性，以及製定策略性彈性規劃以保障醫療服務連續性的必要性。

按泵類型、藥物選擇、治療領域和最終用戶偏好進行細分，凸顯了產品特性與臨床工作流程和支援服務的契合度如何決定產品的成功應用。監管預期和基礎設施的區域差異，使得市場需要採取更具針對性的策略。競爭優勢日益不僅取決於硬體規格，還取決於服務品質、實證醫學證據產生和數位化整合。

展望未來，那些整合可靠的真實世界證據計畫、投資遠端監測並增強供應鏈靈活性的相關人員，將更有利於擴大治療覆蓋範圍並展現長期價值。製造商、臨床網路和支付方之間的合作將加速療法的推廣應用，並確保鞘內療法能夠為患有複雜疼痛和痙攣的患者帶來切實有效的治療效果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • MRI相容型鞘內幫浦的日益普及提高了診斷影像的安全性。
  • 擴展鞘內泵系統中遠端患者監護整合，以實現即時治療調整
  • 越來越重視微創填充和可程式設計藥物輸送脊髓內泵設計
  • 人們對透過標靶脊椎給藥進行鴉片類藥物替代鎮痛的興趣日益濃厚
  • 監管部門的核准加速了下一代可充電鞘內泵技術的市場應用
  • 開發用於自動劑量控制和併發症檢測的智慧感測器
  • 成本效益和報銷壓力影響醫院對鞘內泵的採用。
  • 新興市場對鞘內泵療法的接受度提高，主要得益於夥伴關係和在地化生產。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依泵浦類型分類的鞘內泵浦市場

  • 外置泵
  • 植入式幫浦

9. 依藥物類型分類的鞘內幫浦市場

  • Baclofen
  • 局部麻醉劑
  • 鴉片類藥物

第10章 依治療領域分類的鞘內幫浦市場

  • 疼痛管理
    • 癌症痛
    • 慢性非癌性疼痛
  • 痙攣管理
    • 腦性麻痹
    • 多發性硬化症
    • 脊髓損傷

第11章 鞘內幫浦市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 鞘內幫浦市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 鞘內幫浦市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國鞘內幫浦市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Medtronic plc
    • Flowonix Medical, Inc.
    • Tricumed Medizintechnik GmbH
    • Teleflex Inc.
    • Johnson & Johnson Services Inc.
Product Code: MRR-205091A8875F

The Intrathecal Pumps Market is projected to grow by USD 991.61 million at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 495.22 million
Estimated Year [2025] USD 540.67 million
Forecast Year [2032] USD 991.61 million
CAGR (%) 9.06%

An authoritative introduction that frames intrathecal pump therapy evolution, clinical priorities, regulatory expectations, and stakeholder decision drivers shaping adoption

Intrathecal pump therapy has matured from a niche clinical intervention to a central tool for managing complex pain and spasticity when systemic therapies fail or cause unacceptable side effects. Over the past decade clinicians have expanded indications and refined patient selection, while technologists have improved device reliability, drug delivery precision, and programmability. As a result, the intrathecal pump ecosystem now intersects diverse stakeholders: implanting physicians, device manufacturers, hospital procurement teams, ambulatory centers, payers, and patients seeking durable symptom control with fewer systemic risks.

The introduction of advanced infusion algorithms and integrated telemetric monitoring has shifted discussions from simply whether to use intrathecal delivery toward how to optimize long-term therapy in outpatient settings. Concurrently, regulatory agencies have sharpened focus on post-market surveillance and device-human interface risks, prompting manufacturers to invest in clinical evidence and lifecycle management. Taken together, these developments demand that clinical leaders and commercial strategists navigate a more complex environment where safety, outcomes, service, and cost-efficiency determine adoption trajectories rather than device novelty alone.

This executive summary synthesizes the clinical, commercial, and policy dynamics shaping intrathecal pump therapy today. It frames the transformational shifts influencing stakeholder decisions, highlights tariff-driven supply chain implications for 2025, and distills segmentation, regional, and competitive insights actors must consider. The goal is to provide a coherent, actionable foundation for executives and clinical leaders to align product development, market access, and operational strategies with evolving patient and system needs.

How converging innovations in device engineering, remote monitoring, clinical practices, and regulatory expectations are reshaping adoption pathways and care delivery models

The intrathecal pump landscape is undergoing transformative shifts driven by converging forces in technology, clinical practice, and healthcare delivery models. Device-level innovation has prioritized longevity and precision; batteries and catheter interfaces have seen incremental improvements that reduce revision rates and improve patient convenience. Simultaneously, the integration of remote monitoring and digital telemetry is enabling earlier detection of device-related complications and more responsive dose titration, which in turn influences follow-up workflows and clinic resource allocation.

Clinical practice is shifting from episodic in-clinic programming to hybrid monitoring models that combine periodic in-person assessments with data-driven remote adjustments. This evolution supports broader use of ambulatory surgical centers for implantation and follow-up, altering traditional hospital-centered referral patterns. At the same time, heightened attention to opioid stewardship and growing evidence for intrathecal baclofen in spasticity care have expanded conversations around patient selection criteria and long-term management pathways. These clinical shifts are creating new expectations for evidence generation, patient education, and multidisciplinary care coordination.

Regulatory and reimbursement environments are also evolving. Agencies are prioritizing robust post-market surveillance and clearer labeling on device-drug combinations, requiring manufacturers to demonstrate lifecycle safety. Payers are scrutinizing long-term value propositions more closely, looking beyond acute procedural costs to outcomes such as reduction in systemic drug use, hospitalization, and caregiver burden. As a result, commercial strategies increasingly emphasize real-world evidence collection, value-based contracting pilots, and partnerships with health systems to demonstrate integrated care pathways that support both clinical outcomes and economic objectives.

Taken together, these transformative shifts are reshaping not just product roadmaps but also the operational and commercial architectures required to scale intrathecal therapies. Effective stakeholders will be those that harmonize device performance with care delivery innovations and evidence generation to lower barriers to adoption and secure long-term therapeutic partnerships with providers and payers.

A focused analysis of how 2025 tariff shifts forced rapid supply chain adaptation, procurement strategies, and design changes to protect clinical continuity and margins

Trade policy changes and tariff adjustments in 2025 introduced a new variable into intrathecal pump supply chains and procurement strategies. Increased duties on select medical device components and imported subassemblies elevated input costs for manufacturers that rely on geographically distributed production networks. In response, organizations accelerated supplier diversification strategies, re-evaluated sourcing footprints, and prioritized supplier contracts that provide greater transparency and flexibility around lead times and pricing. These supply-side responses have been complemented by operational changes such as increased inventory buffers for critical catheter and electronic components and more rigorous component qualification processes.

Clinicians and hospital procurement teams observed the downstream effects through intermittent lead-time extensions and more frequent allocation prioritization for urgent cases. Ambulatory surgical centers reported heightened attention to stock management as shorter-term suppliers struggled to absorb tariff-related cost pressures. In parallel, some manufacturers implemented targeted price adjustments or revised service contracts to offset increased input costs while protecting access to essential therapies for high-acuity patients.

Policy uncertainty surrounding tariff permanence encouraged several strategic pivots that may endure beyond 2025. Manufacturers intensified nearshoring and localization efforts to reduce exposure to cross-border duties, while contract manufacturers expanded capacities in lower-tariff jurisdictions. Additionally, there was accelerated interest in design-for-supply resilience, where component standardization and modularization reduce dependence on single-source, tariff-exposed parts. These adaptations improved medium-term supply continuity but also required capital investment and cross-functional coordination, affecting short-term margins and product rollout timelines.

For healthcare leaders, the lesson from the 2025 tariff environment is that supply chain resilience is now a strategic dimension of clinical continuity planning. Procurement teams and device sponsors increasingly collaborate on contingency planning, including dual-sourcing strategies and visibility into upstream supplier risk. As tariff volatility persists as a planning consideration, organizations that embed flexible sourcing, buffer strategies, and proactive supplier engagement into their operating models will be better positioned to sustain therapy availability and protect patient care pathways.

Comprehensive segmentation insights revealing how device type, drug selection, therapeutic indication, and care setting intersect to determine clinical workflows and commercialization tactics

Understanding outcomes and commercialization pathways requires a granular view of the product and clinical segmentation that structures the intrathecal pump landscape. Based on pump type, the therapeutic continuum spans externally wearable infusion systems intended for short-term or hospital-based use and implantable pumps designed for chronic long-term intrathecal therapy, each presenting distinct usability, infection control, and maintenance considerations. These device categories inform clinician workflows and influence where care is delivered; implantable systems typically demand surgically oriented settings and long-term follow-up infrastructure, whereas external devices often align to acute or transitional care episodes.

Drug formulation and compatibility directly shape clinical protocols and labeling. Based on drug type, intrathecal therapy incorporates agents such as baclofen for targeted spasticity control, local anesthetics that permit regional analgesia, and opioids deployed for refractory cancer and severe chronic pain. Each drug class brings unique tolerance profiles, dosing paradigms, and monitoring requirements, and clinicians calibrate device programming and follow-up frequency to mitigate risks like catheter-related granulomas or systemic adverse effects. The selection of an intrathecal agent therefore tightly couples pharmacology with device selection and patient counseling.

Therapeutic application further refines care pathways. Based on therapy area, intrathecal interventions serve pain management and spasticity management domains. Pain management itself divides into cancer pain and chronic noncancer pain, with implant choice, opioid stewardship practices, and palliative care integration differing substantially between these populations. Spasticity management encompasses conditions such as cerebral palsy, multiple sclerosis, and spinal cord injury, each with distinct functional goals, multidisciplinary care needs, and long-term rehabilitation implications. Tailoring device features and service models to these clinical subpopulations enhances adherence and functional outcomes.

End-user dynamics are equally influential for deployment and service models. Based on end user, adoption pathways include ambulatory surgical centers, hospitals, and specialty clinics, each carrying different operational capabilities, reimbursement environments, and staffing models. Ambulatory surgical centers are increasingly attractive for elective implant procedures due to efficiency and patient preference, whereas hospitals often manage more medically complex cases and perioperative risks. Specialty clinics that provide longitudinal device programming and multidisciplinary follow-up are essential for maintaining therapy effectiveness and capturing outcomes data. Recognizing how these segmentation lenses intersect is critical for designing go-to-market approaches, clinician education programs, and long-term service offerings that align with real-world care delivery.

Key regional insights explaining how distinct regulatory, reimbursement, and infrastructure realities across the Americas, EMEA, and Asia-Pacific shape adoption and access strategies

Regional dynamics influence clinical adoption, regulatory engagement, and supply chain design across the intrathecal pump landscape. In the Americas, a dense network of academic centers and community hospitals has supported early adoption combined with robust post-approval clinical research. This region's reimbursement complexity and payer scrutiny influence how sponsors prioritize evidence generation, while consolidated hospital systems enable integrated care pathways that support long-term follow-up and device maintenance. Consequently, manufacturers often align market access strategies with health system evidence needs and value demonstration pilots.

Europe, the Middle East, and Africa present heterogeneous regulatory and reimbursement environments that compel flexible market-entry strategies. Western European countries generally emphasize comparative effectiveness and health technology assessment frameworks, prompting manufacturers to invest in real-world outcomes and cost-effectiveness studies. In contrast, parts of the Middle East and Africa may prioritize access and infrastructure development, creating opportunities for targeted capacity-building programs and local partnerships. Cross-border regulatory harmonization efforts and centralized procurement mechanisms in certain jurisdictions can accelerate technology adoption when evidence and service support are aligned.

Asia-Pacific exhibits a mix of mature markets with established regulatory pathways and emerging markets characterized by rapid investment in specialty care infrastructure. In advanced economies within the region, clinical innovators and private healthcare systems drive demand for high-performance devices and integrated service models. In emerging markets, demand is often shaped by investments in surgical capacity, changing disease burdens, and localized reimbursement decisions. Manufacturers seeking regional scale frequently adopt hybrid approaches that combine direct presence in mature markets with distributor partnerships and training programs in developing markets to ensure appropriate clinical adoption and continuity of care.

Across regions, common themes emerge: the necessity of local evidence generation, the importance of training clinical teams for implantation and follow-up, and the value of supply chain resilience. Tailoring commercial and clinical strategies to regional regulatory, payer, and infrastructural realities accelerates adoption while ensuring therapies remain accessible and clinically effective across diverse healthcare systems.

Key company-level insights showing how established manufacturers and innovative entrants compete through clinical evidence, service models, and software-enabled differentiation

Competitive dynamics in the intrathecal pump space reflect a balance between incumbent device reliability and the emergence of specialized innovators targeting niche clinical needs. Established manufacturers maintain advantages through long-term clinical data, extensive service networks, and integrated training programs that reduce implantation risk and support follow-up care. These capabilities foster institutional trust and simplify procurement decisions for hospitals and specialty clinics where clinical teams demand high reliability and robust post-market support.

At the same time, newer entrants and adjacent medical technology firms are differentiating through software-enabled features, remote monitoring, and modular design concepts that emphasize ease of programming and reduced maintenance burden. Such offerings appeal to health systems focused on outpatient care models and to specialists seeking finer titration capabilities. Collaboration between device developers and pharmaceutical sponsors has also intensified, particularly for drug-device combination strategies where co-development can streamline labeling and clinical trial design.

Service and commercial models are increasingly central to competitive positioning. Companies that offer comprehensive clinician training, local technical support, and transparent warranty and replacement policies create stickiness in clinical pathways. Additionally, vendors that invest in outcomes registries and real-world evidence initiatives build stronger value narratives with payers and health systems. Strategic partnerships with hospitals, academic centers, and rehabilitation networks further extend reach and support adoption by embedding devices within established care pathways.

For buyers and health system leaders, vendor selection now hinges on a broader set of criteria than device features alone. Total cost of therapy, service quality, evidence commitments, and the ability to collaborate on pathway redesign have become equally important. Consequently, suppliers that integrate clinical support, data services, and flexible commercial arrangements are better positioned to capture long-term partnerships and scale intrathecal therapy within complex care delivery ecosystems.

Actionable recommendations for device makers, clinicians, and payers to align evidence, digital capabilities, supply resilience, and commercial models for sustainable growth

Industry leaders must act decisively to align product roadmaps, clinical evidence generation, and supply chain resilience with evolving care delivery models. First, prioritize integrated value demonstrations that link device performance to clinically meaningful outcomes such as reduced systemic medication use, lower hospitalization rates, and improved functional status for spasticity patients. Engaging payers and large health systems early to design pragmatic evidence collection initiatives will shorten reimbursement deliberations and support value-based contracting pilots.

Second, invest in remote monitoring and telemetric capabilities that enable hybrid follow-up models and reduce the frequency of in-person visits without compromising safety. Remote data streams not only enhance patient convenience but also provide real-world endpoints that strengthen economic narratives. Complement these technical investments with clinician training programs that prepare broader surgical and specialty clinic networks to adopt implantation and programming protocols, which will expand suitable care settings beyond tertiary centers.

Third, build supply chain strategies that emphasize dual sourcing, localized manufacturing where feasible, and design-for-supply approaches that reduce dependence on tariff-exposed components. Strategic inventory management and supplier partnerships can buffer against short-term disruptions while preserving margins. Simultaneously, cultivate partnerships with rehabilitation and palliative care providers to embed intrathecal therapy within multidisciplinary care pathways, thereby improving patient identification and continuity of care.

Finally, structure commercial models around service and outcomes, not just hardware sales. Offer flexible contracting, warranty packages, and outcomes-based components where feasible to align incentives with purchasers. By integrating evidence generation, digital capabilities, and resilient operations into a coherent go-to-market strategy, industry leaders will be better equipped to scale therapies while addressing payer scrutiny and clinician expectations.

A transparent and rigorous research methodology combining clinician interviews, regulatory and literature review, supply chain analysis, and expert validation to ensure actionable insights

This research synthesizes multiple methodologies to ensure rigorous, reproducible insights. Primary research included structured interviews with implanting physicians, procurement leaders, and clinical program managers to capture operational realities, patient selection criteria, and follow-up workflows. These first-hand perspectives were complemented by clinician advisory panel discussions that validated clinical assumptions and highlighted practical barriers to scaling intrathecal therapies in diverse care settings.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and procedural best-practice guidelines to triangulate safety signals and device performance themes. Product technical specifications and service model descriptions were analyzed to identify emerging design trends and vendor capabilities. Additionally, analysis of clinical registry abstracts and published outcomes studies informed the synthesis of therapeutic and safety narratives specific to baclofen therapy, local anesthetic use, and opioid-based intrathecal interventions.

Supply chain and policy analysis drew on customs and trade publications, publicly available tariff schedules, and procurement case studies to assess the operational impact of 2025 tariff changes. Scenario analysis techniques were applied to evaluate plausible supply-side responses, including nearshoring, dual sourcing, and inventory strategies, and to understand their implications for manufacturers and healthcare providers. Throughout the study, findings were validated through cross-functional expert review to ensure practical relevance and factual accuracy.

The research approach prioritized transparency and reproducibility. Data gaps were documented and addressed through follow-up interviews or conservative interpretation, and limitations are clearly delineated to support appropriate application of insights. This methodological rigor ensures that conclusions are grounded in current clinical practice, regulatory realities, and operational constraints faced by stakeholders in the intrathecal pump ecosystem.

A concise conclusion highlighting the strategic imperatives for capturing clinical value, ensuring supply resilience, and aligning evidence with payer and provider needs

Intrathecal pump therapy stands at an inflection point where clinical promise, technological capability, and policy dynamics converge to create new opportunities and responsibilities for stakeholders. Advances in device design and telemetry are enabling safer, more patient-centric care models, while evolving payer expectations and regulatory attention demand stronger evidence and lifecycle stewardship. The 2025 tariff experience underscored the fragility of distributed supply chains and the strategic necessity of resilience planning to protect therapy continuity.

Segmentation across pump type, drug selection, therapy area, and end-user setting highlights that successful adoption depends on aligning product features with clinical workflows and support services. Regional differences in regulatory expectations and infrastructure further require tailored market approaches. Competitive differentiation is increasingly determined by the quality of service, evidence generation, and digital integration rather than hardware specifications alone.

Looking ahead, stakeholders that integrate robust real-world evidence programs, invest in remote monitoring, and fortify supply chain flexibility will be best positioned to expand access and demonstrate long-term value. Collaboration across manufacturers, clinical networks, and payers will accelerate adoption pathways and ensure that intrathecal therapies deliver meaningful outcomes for patients with complex pain and spasticity needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of MRI compatible intrathecal pumps for enhanced imaging safety
  • 5.2. Expansion of remote patient monitoring integration in intrathecal pump systems for real time therapy adjustments
  • 5.3. Growing emphasis on minimally invasive refill and programmable drug delivery intrathecal pump designs
  • 5.4. Increasing focus on opioid sparing pain management through targeted intrathecal drug delivery
  • 5.5. Regulatory approvals driving market uptake of next generation rechargeable intrathecal pump technologies
  • 5.6. Development of smart sensor enabled intrathecal pumps for automated dose control and complication detection
  • 5.7. Pressure on cost effectiveness and reimbursement policies shaping intrathecal pump adoption in hospitals
  • 5.8. Penetration of intrathecal pump therapy in emerging markets fueled by partnerships and local manufacturing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intrathecal Pumps Market, by Pump Type

  • 8.1. External Pumps
  • 8.2. Implantable Pumps

9. Intrathecal Pumps Market, by Drug Type

  • 9.1. Baclofen
  • 9.2. Local Anesthetics
  • 9.3. Opioids

10. Intrathecal Pumps Market, by Therapy Area

  • 10.1. Pain Management
    • 10.1.1. Cancer Pain
    • 10.1.2. Chronic Noncancer Pain
  • 10.2. Spasticity Management
    • 10.2.1. Cerebral Palsy
    • 10.2.2. Multiple Sclerosis
    • 10.2.3. Spinal Cord Injury

11. Intrathecal Pumps Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Intrathecal Pumps Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intrathecal Pumps Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intrathecal Pumps Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Flowonix Medical, Inc.
    • 15.3.3. Tricumed Medizintechnik GmbH
    • 15.3.4. Teleflex Inc.
    • 15.3.5. Johnson & Johnson Services Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INTRATHECAL PUMPS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INTRATHECAL PUMPS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRATHECAL PUMPS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. GCC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. GCC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. GCC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. GCC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 244. GCC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 245. GCC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 246. GCC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 247. GCC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 248. GCC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 249. GCC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GCC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. G7 INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. G7 INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. G7 INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. G7 INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 286. G7 INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 287. G7 INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 288. G7 INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 289. G7 INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 290. G7 INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 291. G7 INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. G7 INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NATO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NATO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NATO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. NATO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 300. NATO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 301. NATO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 302. NATO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 303. NATO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 304. NATO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 305. NATO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NATO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. CANADA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. CANADA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. CANADA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 326. CANADA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 330. CANADA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 331. CANADA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. CANADA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 338. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 339. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 340. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 341. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 342. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 343. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. MEXICO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. BRAZIL INTRATHECAL PUMPS MARKET SIZE, BY PUMP T